Markov models for CEA in R

Fernando Alarid-Escudero, PhD* Eric Jutkowitz, PhD[†] Karen M. Kuntz, ScD* 2018-01-11

Contents

1	Model Description
2	Markov structure: Usual care
	2.1 Transition matrix
	2.2 Run Markov model
	2.3 Rewards matrices
	2.4 Compute expected values
3	Markov structure: New treatment
	3.1 Transition matrix
	3.2 Run Markov model
	3.3 Reward matrices
	3.4 Compute expected values
1	Outputs
5	Cost-effectiveness analysis
R	ferences

This document shows an example of how to conduct decision-analytic models in R(Jalal et al. 2017) using the R package dampack.

1 Model Description

We will develop a 4-state Markov model with which to perform an analysis of the expected outcomes for a cohort of 55-year-old women who have undergone tumor excision for localized breast cancer (BCA). After surgery, all patients are initially tumor-free (i.e., will start in the "Local" Markov state). Each year, patients in the Local state face a 2% chance that they will experience a recurrence. Of these recurrences, 75% will present as metastatic disease (and patients will enter the "Mets" Markov state), and the remainder present as local disease (and patients will enter the "Recur" Markov state). Patients in the Recur state undergo repeat resection. Following this operation, they face a 6% chance of recurrence each year. (Assume that all local recurrences - 1st, 2nd, 3rd, etc. - have equivalent prognoses.) Of these recurrences, 90% will present as metastatic disease. Only patients with metastatic disease can die of breast cancer. Finally, all patients in the local and recur state face a 7.6% annual probability of mortality and patients in the metastate face a 39% added risk of death.

The Markov model described above represents usual care for women with breast cancer. Once we construct that Markov model, we will then add a second strategy of a hypothetical new treatment. The effect of this new treatment is to reduce the initial rate of cancer recurrence by 50%; however, the treatment also lowers

^{*}Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA

[†]Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, USA

the quality of life of women taking the medication because of side effects. Treatment is only taken by women who have not experienced a recurrence (i.e., those who reside in the Local state). The Markov model for the treatment strategy will be structurally identical to that of the usual care strategy.

After comparing the two strategies based on quality-adjusted life expectancy (QALE) and costs, we will incorporate costs and calculate the incremental cost per quality-adjusted life year (QALY) gained of treatment compared with usual care.

2 Markov structure: Usual care

The cancer model consists of 4-states (Local, Mets, Recur, and Dead). Therefore, we will be creating a 4x4 transition matrix. We start by labeling the states in the transition matrix.

```
state.names <- c("Local", "Recur", "Mets", "Dead")</pre>
```

We then define the number of states in the model.

```
n.s <- length(state.names)</pre>
```

From the decision problem, we know that patients in the local state face a 2% chance of recurrence under usual care (defined as p.BCA1). Of these recurrences, 75% will present as metastatic disease (and patients will enter the "Mets" Markov state; defined as p.Mets1), and the remainder present as local disease (and patients will enter the "Recur" Markov state; i.e., 1-p.Mets1). We will create variables to represent these probabilities of the transition matrix. Patients in the recur state face a 6% chance of recurrence each year (defined as p.BCA2). Of these recurrences, 90% will present as metastatic disease (defined as p.Mets2).

All patients in the local and recur state face a 0.076 annual rate of dying from non-BCA-related causes, μ_{Die} (defined as mu.Die in R). Patients in the Mets state face a 0.5 anual rate of of dying of metastatic cancer in addition to dying from other causes, $\mu_{DieMets}$ (defined as mu.DieMets in R).

To compute the annual probability of dying from non-BCA-related causes (defined as p.Die in R) we transform the annual rate assuming constant exponential rate

$$p_{Die} = 1 - exp(-\mu_{Die})$$

The overall annual mortality rate for women with metastatic disease is equal to the sum of the rates of dying from other causes and the excess disease-specific mortality rate (defined as muMets). Therefore, the annual probability of dying in the Mets state (defined as p.DieMets in R) is converted by summing these rates to an convert them to annual probabilities

$$p_{DieMets} = 1 - exp(-(\mu_{Die} + \mu_{DieMets}))$$

The annual costs of breast cancer in the Local, Recur and Mets states (c.Local, c.Recur, and c.Mets, respectively) will be the same for both strategies. Table 1 shows parameters of the model of usual care.

Table 1: Table of parameters.

Parameter	R name	Value
Time horizon (n_t)	n.t	51 years
Annual discount rate (costs/QALYs)	d.c/d.e	3%
Annual probability of recurrence	p.BCA1	0.02
after first local tumor diagnosis		
under usual care		
Hazard ratio of recurrence	hr.Recur	0.5
under new treatment		

Parameter	R name	Value	
Proportion of metastatic disease	p.Mets1	0.75	
of recurrences from the Local state			
Annual probability of recurrence	p.BCA2	0.06	
after > 1 local tumor diagnoses	_		
Proportion of metastatic disease	p.Mets2	0.90	
of recurrences from the Recur state	-		
Annual mortality			
- All-cause mortality rate	mu.Die	0.08 or age-specific	
- Cancer specific mortality rate	mu.DieMets	0.5	
Annual costs			
- Cost of new treatment	c.Rx	1000	
- Local state	c.Local	500	
- Recur state	c.Recur	5000	
- Mets state	c.Mets	20000	
Utilities			
- Local state under usual care	u.Local	0.95	
- Recur state	u.Recur	0.80	
- Mets state	u.Mets	0.40	
- Dead state	u.Dead	0.00	
Intervention effect			
- Utility decrement of new treatment	du.Local	0.05	
on women in Local state			

We input the parameters in R as follows:

```
n.t
          <- 51
          <- 0.03
d.c
d.e
         <- 0.03
        <- 0.02
p.BCA1
hr.Recur <- 0.5
p.BCA1.Rx <- 1-exp(log(1-p.BCA1)*hr.Recur)</pre>
p.Mets1 <- 0.75
p.BCA2
         <- 0.06
p.Mets2 <- 0.90
mu.Die
         <- 0.08 # Mean hazard
        <- 1 - exp(-mu.Die)
p.Die
mu.DieMets <- 0.5
p.DieMets <- 1 - exp(-(mu.Die + mu.DieMets))</pre>
u.Local <- 0.95
du.Local <- 0.05
u.Recur <- 0.80
       <- 0.40
u.Mets
u.Dead <- 0.00
c.Local <- 500
c.Recur <- 5000
c.Mets
         <- 20000
c.Rx <- 1000
```

2.1 Transition matrix

To construct the transition matrix for the usual care (UC) strategy, we first need to define a matrix in R that we will name m.P.UC.

Each row in m.P.UC represent a health state and each of its elements store the transition probabilities from that particular state. We need to manually store each of these transition probabilities into the matrix.

```
# Fill in matrix
# From Local
m.P.UC["Local", "Local"] <- (1 - p.Die) * (1 - p.BCA1)
m.P.UC["Local", "Recur"] <- (1 - p.Die) * p.BCA1 * (1 - p.Mets1)
m.P.UC["Local", "Mets"] <- (1 - p.Die) * p.BCA1 * p.Mets1
m.P.UC["Local", "Dead"] <- p.Die
# From Recur
m.P.UC["Recur", "Local"] <- 0
m.P.UC["Recur", "Recur"] <- (1 - p.Die) * ((1 - p.BCA2) + (p.BCA2 * (1 - p.Mets2)))
m.P.UC["Recur", "Mets"] <- (1-p.Die)*p.BCA2*p.Mets2
m.P.UC["Recur", "Dead"] <- p.Die
# From Mets
m.P.UC["Mets", "Local"]
m.P.UC["Mets", "Recur"]
                        <- 0
m.P.UC["Mets", "Mets"]
                         <- 1 - p.DieMets
m.P.UC["Mets", "Dead"]
                         <- p.DieMets
# From Dead
m.P.UC["Dead", "Local"]
                         <- 0
m.P.UC["Dead", "Recur"]
                         <- 0
m.P.UC["Dead", "Mets"]
                         <- 0
m.P.UC["Dead", "Dead"]
                         <- 1
```

We assume that all women start in the Local state, therefore the initial state vector defined as 's0'

```
s0 <- c(1, 0, 0, 0) # Everyone starts in the local state
```

2.2 Run Markov model

All of the components necessary to run the Markov model are now in place. We use the function CalculateMarkovTrace from the dampack package to run the model. The function requires a transition probability matrix, m.P.UC, in this case, the initial state vector (s0), and the number of cycles we want the model to run, n.t. The function produces a list with the cohort trace and the transition array, which we will call m.Markov.UC for the UC strategy.

```
1.Markov.UC <- CalculateMarkovTrace(M = m.P.UC, p0 = s0, n.cycles = n.t)
```

2.3 Rewards matrices

To calculate life years, quality adjusted life years, and cost, we will specify a reward matrix for each of these outcomes. The elements of each of the columns of these matrices must contain the state rewards of the state corresponding to that column.

For the life years, for each year spent in any of the non-dead states, the cohort will get one year of life. That is, the elements of all the columns corresponding non-dead states equal to one.

```
m.LY.UC \leftarrow matrix(rep(c(1, 1, 1, 0), (n.s-1)),
                   byrow = TRUE,
                   nrow = n.s, ncol = n.s,
                    dimnames = list(state.names, state.names))
m.LY.UC
##
          Local Recur Mets Dead
## Local
              1
                     1
                                0
## Recur
                     1
              1
                          1
                                0
## Mets
              1
                     1
                          1
                                0
## Dead
              1
                     1
                          1
```

For the QALY, we follow the similar procedure than for the LY's reward matrix but now each column has the utilities that correspond that particular state

```
the utilities that correspond that particular state
m.QALY.UC <- matrix(rep(c(u.Local, u.Recur, u.Mets, u.Dead), n.s),</pre>
                     byrow = TRUE,
                 nrow = n.s, ncol = n.s,
                  dimnames = list(state.names, state.names))
m.QALY.UC
##
         Local Recur Mets Dead
## Local
          0.95
                 0.8 0.4
## Recur 0.95
                  0.8 0.4
                              0
## Mets
          0.95
                  0.8 0.4
                              0
## Dead
          0.95
                 0.8 0.4
                              0
m.C.UC <- matrix(rep(c(c.Local, c.Recur, c.Mets, 0), n.s),</pre>
                  byrow = TRUE,
                 nrow = n.s, ncol = n.s,
                  dimnames = list(state.names, state.names))
m.C.UC
##
         Local Recur Mets Dead
## Local
           500 5000 20000
           500 5000 20000
## Recur
                               0
## Mets
           500 5000 20000
                               0
```

2.4 Compute expected values

500 5000 20000

0

Using the ExpectedValue function from the dampack package, we calculate the expected life years of the Markov cohort under usual care. In the expected value function we input the transition array (generated from the CalculateMarkovTrace function), the reward matrix for life years m.LY.UC, discount rate d.e and ask to conduct a half cycle correction.

```
## [1] 8.213022
```

Dead

To compute the expected QALYs, we follow the same procedure but now using the reward matrix for QALYs $\mathtt{m.QALY.UC}$

[1] 7.61944

To compute the expected costs, we follow the same procedure but now using the reward matrix for costs $\mathtt{m.C.UC}$

[1] 10395.49

3 Markov structure: New treatment

Table 1 shows parameters of the model of the new treatment.

3.1 Transition matrix

```
# Initialize matrix
m.P.Rx <- matrix(0,
                 nrow = n.s, ncol = n.s,
                 dimnames = list(state.names, state.names))
# Fill in matrix
# From Local
m.P.Rx["Local", "Local"] <- (1 - p.Die) * (1 - p.BCA1.Rx)
m.P.Rx["Local", "Recur"] <- (1 - p.Die) * p.BCA1.Rx * (1 - p.Mets1)
m.P.Rx["Local", "Mets"] <- (1 - p.Die) * p.BCA1.Rx * p.Mets1
m.P.Rx["Local", "Dead"] <- p.Die
# From Recur
m.P.Rx["Recur", "Local"] <- 0
m.P.Rx["Recur", "Recur"] <- (1 - p.Die) * ((1 - p.BCA2) + (p.BCA2 * (1 - p.Mets2)))
m.P.Rx["Recur", "Mets"] <- (1-p.Die)*p.BCA2*p.Mets2
m.P.Rx["Recur", "Dead"] <- p.Die
# From Mets
m.P.Rx["Mets", "Local"] <- 0
m.P.Rx["Mets", "Recur"] <- 0
m.P.Rx["Mets", "Mets"] <- 1 - p.DieMets
m.P.Rx["Mets", "Dead"] <- p.DieMets
# From Dead
m.P.Rx["Dead", "Local"] <- 0</pre>
m.P.Rx["Dead", "Recur"] <- 0
m.P.Rx["Dead", "Mets"]
                         <- 0
m.P.Rx["Dead", "Dead"]
                       <- 1
```

3.2 Run Markov model

```
1.Markov.Rx <- CalculateMarkovTrace(M = m.P.Rx, p0 = s0, n.cycles = n.t)
```

3.3 Reward matrices

The LY's reward matrix for Rx is the same than for UC.

```
m.LY.Rx <- m.LY.UC
```

```
The reward matrix for Rx changes by adding the disutility from the treatment to the Local state.
m.QALY.Rx <- matrix(rep(c(u.Local-du.Local, u.Recur, u.Mets, u.Dead), n.s),
                    byrow = TRUE,
                 nrow = n.s, ncol = n.s,
                 dimnames = list(state.names, state.names))
m.QALY.Rx
##
         Local Recur Mets Dead
           0.9
                 0.8 0.4
## Local
## Recur
           0.9
                 0.8 0.4
                             0
## Mets
           0.9
                0.8 0.4
                             0
## Dead
           0.9
                 0.8 0.4
m.C.Rx <- matrix(rep(c(c.Local + c.Rx, c.Recur, c.Mets, 0), n.s),
                 byrow = TRUE,
                 nrow = n.s, ncol = n.s,
                 dimnames = list(state.names, state.names))
m.C.Rx
##
         Local Recur Mets Dead
## Local 1500 5000 20000
## Recur 1500 5000 20000
                              0
## Mets
          1500 5000 20000
                              0
## Dead
         1500 5000 20000
```

3.4 Compute expected values

[1] 8.620571

To compute the expected QALYs, we follow the same procedure but now using the reward matrix for QALYs m.QALY.Rx

[1] 7.673208

To compute the expected costs, we follow the same procedure but now using the reward matrix for costs $\mathtt{m.C.Rx}$

[1] 16061.16

4 Outputs

Table 2 shows the outputs of the Markov model for the two strategies.

Table 2: Outcomes of Markov model by strategy

Strategy	LYs	QALYs	Costs
Usual care	8.21		\$10,395.49
New Treatment	8.62		\$16,061.16

5 Cost-effectiveness analysis

Finally, in Table 3, we show the results for the CEA of the Markov model.

Table 3: CEA of new treatment for breast cancer patients

Strategy	QALYs	Incremental.QALYs	Costs	Incremental.Costs	ICER
Usual care	7.62	-	\$10,395.49	-	-
New Treatment	7.67	0.05	\$16,061.16	\$5,665.66	105,372 / QALY

References

Jalal, Hawre, Petros Pechlivanoglou, Eline Krijkamp, Fernando Alarid-Escudero, Eva A. Enns, and M. G. Myriam Hunink. 2017. "An Overview of R in Health Decision Sciences." *Medical Decision Making* 37 (7): 735–46. doi:10.1177/0272989X16686559.